{"id":287,"date":"2024-05-27T10:00:00","date_gmt":"2024-05-27T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=287"},"modified":"2025-09-10T10:05:40","modified_gmt":"2025-09-10T10:05:40","slug":"technology-collaboration-medilink-and-biontech-expand-the-collaboration-on-several-adc-products","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/287.html","title":{"rendered":"[Technology Collaboration]\u00a0MediLink and BioNTech Expand the Collaboration\u00a0on several ADC products"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2024-05-26 (May 26, 2024)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: MediLink Therapeutics (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee: BioNTech<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech will receive an exclusive option to an exclusive global license to apply MediLink\u2019s TMALIN\u00ae antibody-drug conjugate (ADC) platform, \u00a0for several novel targets chosen by BioNTech.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MediLink will hold the right of first negotiation for future collaboration of these ADC product candidates if BioNTech wishes to exclusively license or assign rights in such ADC product candidates solely on the Mainland China market or Mainland China market together with one or more of the markets including of Hong Kong, Macau or Taiwan region.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MediLink will receive<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of $25 million, <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and sales milestone payments potentially totaling up to $1.8 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties on potential future global annual net sales. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">. MediLink Therapeutics announces a multi-target TMALIN\u00ae ADC technology platform license agreement with BioNTech<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.medilinkthera.com\/news-details\/35\">Medilink Therapeutics<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.  <a href=\"https:\/\/cninmed.com\/en\/2023\/245.html\">[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC\u00a0YL202 (BNT326) \u2013 CninMed \u2013 China Innovative Drugs Update<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of \u201cMediLink Therapeutics\u201c\uff0c\u5b9c\u8054\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-05-26 (May 26, 2024) Licensor: MediLink Therapeutics (China) Licensee: BioNTech . Scope of Authority: &hellip; <a title=\"[Technology Collaboration]\u00a0MediLink and BioNTech Expand the Collaboration\u00a0on several ADC products\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/287.html\"><span class=\"screen-reader-text\">[Technology Collaboration]\u00a0MediLink and BioNTech Expand the Collaboration\u00a0on several ADC products<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,6],"tags":[],"class_list":["post-287","post","type-post","status-publish","format-standard","hentry","category-china-license-out","category-china-tech-corp"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=287"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/287\/revisions"}],"predecessor-version":[{"id":288,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/287\/revisions\/288"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}